Priority Assets


Our Priority Assets are largely maturing clinical development companies, nearing significant value inflection points.

Viamet represents a financial interest in a Phase 3 compound for the treatment of recurrent vulvovaginal candidiasis (RVVC), an unmet need in women's health, and onychomycosis (OM), fungal nail infection.

Viamet’s most advanced molecule, VT-1161, was acquired by NovaQuest Capital Management in January 2018. The acquisition of this molecule followed the successful Phase 2b clinical trials for the treatment of RVVC and OM announced in 2017.

NovaQuest Capital Management will be responsible for the further development of VT-1161. Progress of this molecule will provide a substantial cash flow to Malin.

Viamet Pipeline

Candidate

Indication

IND-enabling

Phase 1

Phase 2

Phase 3

VT-1161
Metalloenzymes

Recurrent vulvovaginal candidiasis (RVVC)

VT-1161
Metalloenzymes

Onychomycosis

VT-1129
Metalloenzymes

Cryptococcal meningitis

Candidate: VT-1161
Metalloenzymes

Indication: Recurrent vulvovaginal candidiasis (RVVC)

IND-enabling

Phase 1

Phase 2

Phase 3

VT-1161
Metalloenzymes

Indication: Onychomycosis

IND-enabling

Phase 1

Phase 2

Phase 3

Candidate: VT-1129
Metalloenzymes

Indication: Cryptococcal meningitis

IND-enabling

Phase 1

Phase 2

Phase 3